07 Dec 2009 Biotest AG: Immunoconjugate BT-062 shows first data of clinical efficacy
07 Dec 2009 Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma
07 Dec 2009 Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
07 Dec 2009 Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
07 Dec 2009 Immunomedics Announces Preclinical Results of Milatuzumab in B-Cell Malignancies
04 Dec 2009 Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma
04 Dec 2009 Biotest AG: European Commission grants approval of Zutectra(R)
03 Dec 2009 Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
03 Dec 2009 Kyto Biopharma Inc. Announces High-Affinity Monoclonal Antibody to the Cellular Receptor for Transcobalamin (Vitamin B12)
02 Dec 2009 Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
01 Dec 2009 Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
01 Dec 2009 Trellis Bioscience Grants MedImmune License for Its Anti-RSV Antibodies
30 Nov 2009 Xencor Licenses Antibody Optimization Technology
24 Nov 2009 Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
23 Nov 2009 Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
23 Nov 2009 GLYCOTOPE receives regulatory approval for GlycoExpress Technology and initiates first clinical trial with lead antibody GT-MAB 2.5 GEX
20 Nov 2009 ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
20 Nov 2009 ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology
19 Nov 2009 Merck KGaA: CHMP Opinion for Erbitux in Advanced Non-Small Cell Lung Cancer
18 Nov 2009 Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma
18 Nov 2009 Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
17 Nov 2009 Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
17 Nov 2009 Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
17 Nov 2009 ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up